Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
- Volume Zscore is a recent 2 week high. A recent surge of ZScore means trading activities is accelerating at a record speed.
- Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
|Earning Growth (QoQ)|
|Revenue Growth (QoQ)|
|Held by Institutions %||73%|
|1 Day Vol Adjusted Return||-1.1|
|1 Month Vol Adjusted Return||-7.3|
|3 Month Vol Adjusted Return||-6.1|
|6 Month Vol Adjusted Return||-1.6|
|20 Days SMA Price ZScore||-2.0|
|50 Days SMA Price ZScore||-2.7|
|12 -26 Days PPO||-7.8|
|1 Month Average Short Volume Ratio||39.4|
|1 Day Volume Change ZScore||2.7|
|1 Month Daily Vol||4.7|
Invitae (NYSE: NVTA) is growing revenue quickly thanks to its acquisition of ArcherDx, which offers tests to determine the best drugs to treat tumors. In this video from Motley Fool Live, recorded on Feb. 22, Fool.com contributors Brian Orelli and Keith Speights discuss how Invitae's top-line growth should eventually benefit the company's bottom line.
Shares of Invitae (NYSE: NVTA) were down 8.6% as of 3:30 p.m. EST on Thursday. Invitae hasn't announced any news that would cause its shares to slump. Investors shouldn't be alarmed by Invitae's pullback.
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will present at the Oppenheimer 31st Annual Healthcare Conference on Tuesday, March 16, 2021 at 10:40 a.m. Eastern / 7:40 a.m. Pacific.
The past 12 months have been a wild ride for the genetic testing company's stock, with a sub-$10 low and a high of more than $60.
What happened Shares of Invitae (NYSE: NVTA) had fallen 6.6% as of 3:13 p.m. EST on Wednesday. The medical genetics company didn't announce any news that would cause the stock to drop. Instead, Invitae's decline today appears to be part of a broader sell-off of high-growth stocks, with the Nasdaq Composite Index falling 2%.
Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs, in collaboration with Invitae Corporation (NYSE: NVTA, "Invitae"), a leading medical genetics company, announces the launch of a sponsored genetic testing program, navigateAPDS, designed to assist clinicians in identify...
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the addition of tools from Medneon, a digital health AI company, to its robust clinical workflow and patient education tools. The additional capabilities further support clinicians and patients with cancer by making it easier to determine who should get testing and how to use genetic information to individualize treatment.
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of NEXT plc ( LON:NXT...
Invitae's stock was down by 8.4% as of 1:06 p.m. EST today, after falling by as much as 15.2% earlier in the day. Instead, Invitae is likely guilty of general stock market volatility. As of this writing, all three major U.S. stock market indexes are down.
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced expanded capabilities that enable clinicians to use its advanced clinical chatbot Gia to guide their patients in an intuitive, enjoyable and telemedicine-friendly conversation through receiving and understanding genetic test results and possible next steps, including scheduling a call with a genetics counselor.